USPTO serial 79363664
STIPE THERAPEUTICS
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Apr 2, 2024
- Examiner
- BIBB, SCOTT
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with STIPE THERAPEUTICS?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Shoko Naruo
Shoko Naruo Thompson Coburn LLPOne US Bank PlazaSt. Louis, MO 63101UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Chemicals for use in industry and science; chemicals for use in manufacture of peptides, small molecules, and a wide variety of goods; biological preparations for use in industry and science; biological preparations for use in manufacture; chemicals and chemical preparations for use in the manufacture of pharmaceuticals; chemicals and chemical preparations for use in the pharmaceutical industry, namely, active chemical ingredients for use in the manufacture of pharmaceuticals for treating cancer, tumorigenesis, autoimmune disorders, and other inflammatory diseases; chemicals and chemical preparations for use in biotechnological manufacturing processes; chemical and chemical preparations for use in biotechnological product development; chemicals and chemical preparations for use in the biotechnological industry; reagents for scientific purposes; reagents for medical research; enzymes for scientific purposes; enzymes for use in the manufacture of pharmaceuticals; biological preparations other than for medical use; proteins for use in industry and science; proteins for use in manufacture; peptides for use in industry and science; peptides for use in manufacture of pharmaceuticals | ACTIVE | — |
| 005 | Pharmaceutical preparations for the prevention of cancer, tumorigenesis, autoimmune disorders, and other inflammatory diseases, medical preparations for the treatment of cancer, tumorigenesis, autoimmune disorders, and other inflammatory diseases, and veterinary pharmaceutical preparations for the treatment of cancer, tumorigenesis, autoimmune disorders, and other inflammatory diseases; medical preparations, namely, adjuvants used in vaccines; sanitary preparations for medical purposes; dietetic food and preparations adapted for medical or veterinary use, food for babies; dietary supplements for human beings and animals; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides; pharmaceuticals for the treatment of cancer and autoimmune disorders; drug delivery agents in the form of intravenous administration fluids that facilitate the delivery of pharmaceutical preparations; synthetic proteins and peptides for pharmaceutical and medical purposes, namely, for the treatment of cancer, tumorigenesis, autoimmune disorders, and other inflammatory diseases; regulatory proteins and peptides for pharmaceutical and medical use, namely, protein arrays for treating cancer, tumorigenesis, autoimmune disorders, and other inflammatory diseases | ACTIVE | — |
| 042 | Design and development of computer hardware and software; clinical research in the field of cancer, tumorigenesis, autoimmune disorders, and other inflammatory diseases; medical and scientific research, namely, conducting clinical trials for others; drug discovery services; development of pharmaceutical preparations and medicines; research relating to medicines; medical and pharmacological research services; medical laboratories; scientific and technological services, namely, research and design in the field of medical technology; product design and development of medical apparatus; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; providing medical and scientific research information relating to medical and veterinary research and development | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by STIPE Therapeutics ApS
- Other trademarks owned by STIPE Therapeutics ApS
- Other trademarks owned by STIPE Therapeutics ApS
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 042
- Similar marks named STIPE THERAPEUTICS
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Nov 9, 2024 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Oct 18, 2024 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Oct 18, 2024 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Jul 3, 2024 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Apr 2, 2024 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Apr 2, 2024 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Jan 16, 2024 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jan 16, 2024 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jan 13, 2024 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Dec 27, 2023 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Dec 27, 2023 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Dec 27, 2023 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Dec 13, 2023 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Nov 16, 2023 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Nov 16, 2023 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Nov 16, 2023 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Nov 13, 2023 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Nov 13, 2023 | ECDR | TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS | — |
| Nov 13, 2023 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Nov 13, 2023 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Nov 13, 2023 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Nov 13, 2023 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Oct 6, 2023 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Jun 26, 2023 | RFNT | REFUSAL PROCESSED BY IB | — |
| Jun 7, 2023 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Jun 7, 2023 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Apr 18, 2023 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Apr 17, 2023 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Apr 13, 2023 | DOCK | ASSIGNED TO EXAMINER | — |
| Mar 1, 2023 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Feb 25, 2023 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Feb 24, 2023 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |